A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study
Eur J Cancer. 2025 Aug 20;229:115693. doi: 10.1016/j.ejca.2025.115693. Online ahead of print. ABSTRACT BACKGROUND: Osimertinib is commonly used as a […]
